PDL Biopharma Inc (PDLI) Com Stk USD0.01
PDL BioPharma, Inc. is focused on developing therapeutics and healthcare technologies. Through its subsidiary, LENSAR, Inc., the Company provides medical devices. It is focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It has developed the LENSAR Laser System, which is the femtosecond cataract laser built for refractive cataract surgery. LENSAR Laser System offers cataract surgeons automation and customization for their astigmatism treatment planning and other steps of the refractive cataract surgery procedure. It assists surgeons in managing their astigmatism treatment plans for optimal overall visual outcomes.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.